問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


National Taiwan University Hospital (在職)

Division of Others-Department of Laboratory Medicine

Division of General Internal Medicine

Division of Hematology & Oncology

更新時間：2023-09-19

林建嶔Lin, Chien-Chin
  • Principal Investigator
  • Clinical Trial Experience (year) 17 years 9 個月

Recruiting Trial

116Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

林建嶔

List

165Cases

2021-11-01 - 2024-07-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Recruiting5Sites

2022-03-01 - 2022-08-04

Phase I/II

  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Terminated3Sites

2015-10-30 - 2019-04-27

Phase II

A Phase 2, Open-label, Multiple Ascending Dose Study to Evaluate the Efficacy, Safety, Tolerability, Immunogenicity, Pharmacokinetics, and Pharmacodynamics of ALXN1210 Administered Intravenously to Patients with Paroxysmal Nocturnal Hemoglobinuria

  • Condition/Disease

    Paroxysmal Nocturnal Hemoglobinuria (PNH)

  • Test Drug

    ALXN1210

Participate Sites
2Sites

Terminated2Sites

2016-07-31 - 2022-06-30

Phase II/III

A Phase 2/3 Multicenter, Open-label, 3 arm, 2 stage Randomized Study of ASP2215 (Gilteritinib), Combination of ASP2215 Plus Azacitidine and Azacitidine Alone in the Treatment of Newly Diagnosed Acute Myeloid Leukemia with FLT3 Mutation in Patients Not Eligible for Intensive Induction Chemotherapy

  • Condition/Disease

    Acute Myeloid Leukemia (AML)

  • Test Drug

    ASP2215

Participate Sites
9Sites

Recruiting2Sites

Terminated7Sites

2017-03-17 - 2023-04-17

Phase III

A Multi-center, Randomized, Double-blind, Placebo-controlled Phase III Trial of the FLT3 Inhibitor Gilteritinib Administered as Maintenance Therapy Following Allogeneic Transplant for Patients With FLT3/ITD AML

  • Condition/Disease

    Acute Myeloid Leukemia (AML)

  • Test Drug

    ASP2215

Participate Sites
4Sites

Recruiting3Sites

2022-02-01 - 2025-12-01

Phase II/III

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Not yet recruiting4Sites

2023-06-01 - 2025-12-31

Phase I/II

A Phase 1/2, Open-Label, Dose-Escalation, Dose-Expansion Study of DSP-5336 in Adult Acute Leukemia Patients With and Without Mixed Lineage Leukemia (MLL)-Rearrangement or Nucleophosmin 1 (NPM1) Mutation

  • Condition/Disease

    Leukemia, Myeloid, Acute、 Leukemia, Lymphocytic, Acute

  • Test Drug

    DSP-5336

Participate Sites
3Sites

Recruiting3Sites

2019-01-01 - 2026-04-30

Phase III

A Phase 3, Randomized, Open-label, Parallel-controlled, Multi-center Study Comparing TJ202, Lenalidomide and Dexamethasone vs. Lenalidomide and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma Who Received at Least 1 Prior Line of Treatment

  • Condition/Disease

    Relapsed or Refractory Multiple Myeloma

  • Test Drug

    TJ202

Participate Sites
5Sites

Terminated5Sites

2020-10-20 - 2022-04-28

Phase III

A Phase 3 Multicenter, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Rozanolixizumab in Adult Study Participants With Persistent or Chronic Primary Immune Thrombocytopenia (ITP)

  • Condition/Disease

    Primary Immune Thrombocytopenia(ITP)

  • Test Drug

    Rozanolixizumab

Participate Sites
5Sites

Not yet recruiting2Sites

Recruiting3Sites

2019-11-15 - 2026-01-31

Phase III

A Phase 3b, Multicenter, Open-Label, Single-Arm Study of Acalabrutinib (ACP-196) in Subjects With Chronic Lymphocytic Leukemia.

  • Condition/Disease

    Chronic Lymphocytic Leukemia

  • Test Drug

    Acalabrutinib (ACP-196)

Participate Sites
4Sites

Recruiting4Sites

1 13 14 15 16 17
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB